In studies investigating the combination of two or more anticancer drugs that are already approved for independent use, or 'maintenance' regimens, the use of progression-free survival as the end point for approval is inadequate; sequential treatment with the same agents or existing salvage therapies, respectively, might provide an equivalent survival benefit, with lower toxicity, cost, and treatment burden, therefore, the use of an overall survival end point is essential to justify such interventions.

中文翻译：

---

结合药物和扩大治疗范围-PFS终点还不够

在研究已被批准可独立使用或“维持”方案的两种或多种抗癌药物组合的研究中，将无进展生存期作为批准的终点是不够的；分别使用相同的药物或现有的挽救疗法进行序贯治疗可能会提供同等的生存益处，同时具有更低的毒性，成本和治疗负担，因此，使用总体生存终点对于证明此类干预措施是必不可少的。